Across TCGA pan-cancer cohorts, CARMIL3 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CARMIL3 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CARMIL3 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CARMIL3 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
BLCA, LUAD, and UCEC are the cancer types where CARMIL3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.